All evidence is gathered. Here is the independent stage retrospective.

---

# Independent stage retrospective (read-only, pre-pause)

**Independence limits, stated up front:** I am GLM-5.3, the same model family as the E03 executor (GLM-5.3-Flash) and C03 conferences (GLM-5.3) I am reviewing — same-family challenge, not family-isolated verification. Text-only route: I did not view the source page images; image-content claims rest on frozen receipt excerpts. I did not run test suites, call models, or read the platform goal API; owner-reported numbers are marked as such. Everything else below was verified against the actual files this session.

## 1. Real release blockers vs. worthwhile-but-nonblocking

**Verified stage state.** Phase 5 and 5.5 are both `in_progress` with `claims_complete=false` (both `task.json`). Stage E's exit requires controlled 31001 rerun, item-by-item 原件 QC of facts/events/exposures/Profile, and stage-F requires the frozen gold-standard evaluation (union recall ≥0.95, zero silent negative misses, full-chain browser verification). None of these exist yet.

**Actual blockers, in order:**

1. **The judgment-search chain is not wired into the product.** I verified by import/call-site scan: `judgment_search_source/results/artifacts/reader` are imported only by each other, the probe script, and tests. Zero references in `app/api`, zero in any job service. There is no durable orchestration and no D2 gap producer. This means the capability the user already authorized on 2026-09-06 (report submitted-scope missing investigator judgment without re-asking the user) **cannot be produced by the product today**. This is the single largest gap between work-invested and user-visible value.
2. **runtime05 normalization is partial** — 37 facts / 5 events / 0 exposures / 54 pending, run state partial (checkpoint line 129, recovery plan §9F). It must not be cited as a current full run; a new full normalization has not been done.
3. **No full-suite zero-failure rerun.** Last full V2 was 4453 passed / 1 failed / 3 skipped; the 1 failure was a test-assumption defect (doc-a ordering), fixed, with 30 targeted passes after. The owner's current aggregate (~130 passed, 12.42 s, owner-reported; 125 test functions verified across 8 judgment-search test files) is focused, not full-suite. Correct to not claim green.
4. **R1 (annotation↔measurement-time binding) and due-stage applicability admission** — the two semantic preconditions the D2 producer depends on — remain undone, as the latest C03 review itself states.

**Nonblocking refinements (do not gate the stage):** batch-v1 call efficiency (1 call/page vs per-target — structure verified working, no E2E speed claim), receipt index/registry over content-addressed bytes, additional calibration samples, high-effort single-factor route (decision to keep low default is already correct), Pi/agent-core embedding (already explicitly deferred in design §4 — the cited reason, "located bottlenecks are not in the agent loop," still holds).

**Not blockers:** the report1 ambiguous-vs-found divergence (GLM ambiguous with uncertainty note vs Gemini found on the same sticky-note annotation — this is the system working as designed: unverified disagreement, correctly not collapsed), and the 46 missing lane-pages per target (correctly reported as `coverage_incomplete` with `professional_judgment_absence_proven=False`).

## 2. Why the micro-cycles don't reach workflow completion

Demonstrable engineering/process causes, separated from speculation:

- **Every cycle terminates at a module boundary, not a product entry point.** The reader/source/assembler/artifact modules are individually excellent (strict single-object JSON, TOCTOU page-byte freezing, load-time re-binding, failure-never-becomes-not_found, `product_acceptance` type-locked False — all verified in code). But the slice discipline has consistently stopped one integration step short: the durable page-review job machinery that this chain needs **already exists and is wired** (`PageReviewJobService`, per checkpoint inventory), and the new chain never plugs into it. Test counts grow (125 functions in 8 files) while the API surface for the feature stays at zero. That is the mechanism by which "stage acceptance cannot be substituted by growing test counts" became literal in this repo.
- **Verification asymmetry.** Enormous adversarial self-verification at the leaf (re-parse, re-validate, re-bind on load; conference re-runs of the same synthetic suites) versus almost no end-to-end state-machine completion. Each conference correctly scopes itself to the delta and marks D2 "out of scope" — so no review ever owns the integration, and integration is the only thing left.
- **Calibration-set saturation in the medication loop.** `MEDICATION_EXPANDED_FINDINGS.md` itself records that 31006 was used for prompt tuning and is no longer an independent holdout, and that v5.1 stopped prompt-stacking only after repeated rounds. The loop shape was: residual divergence (real — dates, dose semantics) → new isolated contract/version → re-run same pages → new divergence. Without a fresh holdout, that loop has no termination condition; the document's own "后续处理" section reaches the same conclusion.
- **Provider behavior, evidence vs. inference.** Evidenced: GLM low confuses dose specification/duration and shortens dates (v5.1); ambiguous-vs-found on the sticky note; two-length failures on dense pages (E-stage, 2026-09-06); lane latency variance 4.9–16.8 s. Not evidence: "the model can't do this" — the high single-factor run corrected dose/duration, and explicit two-target focusing removed disease-status contamination. Several failures attributed to model quality were actually task-shape problems; the correct response (task decomposition, per-page batching) is now in the code, and further re-prompting of the saturated set would be the wrong instrument.
- **Contextual, not user-caused:** the product thread was interleaved with the separate local-model benchmark thread (MTPLX/oMLX diagnostics dominate the checkpoint's middle sections). That split session surface is a resource contention observation, not a product defect, and the user's pause request is not a cause of the circling.

## 3. Stop / defer / retain; is a harness rewrite warranted?

**Defer from active plan:** Pi/agent-core embedding (no demonstrated dynamic-tool need); further medication prompt iterations on 31006 (next medication step = new holdout with a pre-declared non-clinical comparison contract, not v5.3); the 14-group blind rerun and any broad new model comparison (F explicitly gates these behind the sequential preconditions); receipt registry/index polish.

**Stop:** adding further judgment-search leaf contracts, re-validation layers, or assembler variants. The leaf is done to a higher standard than its consumption warrants. The next unit of work is wiring, full stop.

**Retain:** reader v4 + batch v1, source builder, results assembler, artifact save/load, coverage summarizer (all reviewed, sound); `fact_expectation_gaps` shared code with its structured-equality retention logic; runtime04/05 evidence; frozen medication v5/v5.1/v5.2 results; all checkpoints and raw history (nothing is deleted — deferral is an active-plan statement only).

**Harness rewrite: not warranted.** The persistent-job infrastructure the new chain needs already exists and is API-wired for page review; this stage's failure mode was never harness capability. A framework replacement would not solve the actual gaps: D2 producer semantics (due-stage applicability + supplied-scope-only wording), clinical QC of runtime05's 37 facts, gold-standard eval freeze, and Profile/UI surfacing. Those are all unsolved by any harness.

## 4. Minimal vertical slice after the user resumes

One requirement, one subject, frozen inputs, existing models, through to a visible source-limited unresolved reason:

1. **Inputs:** existing runtime05 database (job `ecf027d8…`, 24-page frozen complete processing revision). No new ingestion.
2. **Published requirement:** `prepare_judgment_search_target` already returns scope+target from the live published rule set (verified, including the due-stage/workflow-stage re-checks). Only delta: admit due-stage applicability by reusing the `stage_rank` logic already in `fact_expectation_gaps.py:197-204`.
3. **Two independent reads per page:** reuse `read_judgment_search_page_batch` (batch v1) inside a durable job modeled on the existing targeted-reread executor pattern — lease transaction per successful lane-page, failures persisted with typed failure_kind, retry only by same lane/model. Dependency: none new; this is adaptation, not new orchestration.
4. **Persist/fail-recover:** move receipt storage from the probe's isolated store to the product `ArtifactStore` via the existing `save/load_judgment_search_receipt` (the functions already enforce current-scope re-binding on load — that's the resume mechanism). Recovery test: cancel mid-run → restart → no duplicate lane-page reads, failures typed.
5. **Source-limited unresolved reason:** in `fact_expectation_gaps`, when (and only when) coverage is `all_supplied_pages_searched_without_candidate` on both lanes, due-stage applies, and the requirement needs investigator assessment → gap becomes `PROFESSIONAL_JUDGMENT` with “本次提交资料未见…书面判断” wording (per the 2026-09-06 user confirmation and supplied-absence semantics). Any `coverage_incomplete`/ambiguous/unreadable/missing-file path stays `OBSERVATION_UNVERIFIED` — the current distinction at `fact_expectation_gaps.py:209-227` is exactly right and must be preserved.
6. **Profile/UI:** surface the gap with page + excerpt locator, responsible party, due stage (final design §5.4/§6 wording), in the existing wide-screen layouts.

**Stopping criteria:** slice accepted when one requirement's unresolved reason appears in the UI with an unbroken receipt chain (page image hash → receipt → coverage → gap) and the cancel/resume test passes. Not accepted by: test counts, single-page probes, or model-identity receipts alone. **Not prerequisites:** new benchmarks, Pi migration, new abstraction layers, medication auto-accept (stays isolated until eval + user confirm).

## 5. Defects in the latest batch/storage code

**No actionable critical defect within the reviewed scope** (reader single/batch, source, results, artifacts, coverage, probe, batch-v1 artifacts). Specific non-critical notes:

- `app/services/judgment_search_artifacts.py:46-48` imports the private `_extract_single_json_object` from the reader — coupling nit; make it public if the wiring slice touches it.
- `scripts/run_judgment_search_probe.py:41` engine URL looks malformed (`"sqlite:///" + as_uri()`), but I verified via the project venv's SQLAlchemy dialect `create_connect_args` that it parses to `file:…?mode=ro` with `uri=True` — read-only mode works as intended. Not a defect.
- `summarize_judgment_search_coverage` returns `candidates_present` even when coverage is grossly incomplete (report1 target-0: 1 found alongside 46 missing lane-pages). Gap lists are retained by design, but any future UI must render status and gaps together, never status alone.
- Batch receipts each embed the full `PageCompletion` (verified: 2 receipts share one completion-text hash; 4 content-addressed artifacts per batch directory) — acceptable duplication now, worth noting for volume planning.
- Bounded claim: "no defect" is bounded to leaf + probe scope. The durable orchestration that would exercise true E2E does not exist, so nothing true-E2E was — or could be — reviewed.

## 6. What the owner must disclose in the pause handoff

1. Phase 5/5.5 unclosed; `claims_complete=false`; E/F exit criteria unmet.
2. The platform goal object still carries stale MTPLX-era routing while the product mainline is GLM-5.3-Flash low + Gemini-3.7-Flash high; goal status reads paused via API (both owner-reported — not verifiable from the repo).
3. Shared dirty worktree must be preserved: 2033 entries (1718 untracked + 315 modified) on `codex/phase5-clinical-facts-profile`, including other threads' work; all judgment-search product files are untracked.
4. runtime05 normalization is partial (37/5/0/54) — not a new full run.
5. Test state: last full V2 4453/1/3 (the 1 was a test-assumption defect, fixed, 30 targeted pass); current ~130 focused pass is not full-suite; no zero-failure full rerun exists.
6. Batch-v1 sample is structure-success only: 2 pages × 2 targets, 46 missing lane-pages per target on a 24-page scope, absence not proven. For labeling: cite the frozen `input.json` metadata, not directory nicknames — verified identities: `judgment-source-batch-v1-report1` = page 1 of document `7462fdcc…` (门诊报告页； IN-02:03:01 → Gemini found / GLM ambiguous; EX-07 none) and `…-page9` = page 9 of document `f55350a8…` (检验页； both targets none). Any inventory that swapped these names contradicts the frozen metadata.
7. Medication component matching is isolated experimentation only; 31006 is a saturated calibration set; no auto-acceptance authorization exists.
8. Judgment search has no durable orchestration and no D2 producer; test existence does not constitute wiring (verified: zero `app/api` references).
9. All candidate artifacts are reversible: probe outputs live under `artifacts/phase55-takeover/20260910/` and isolated receipt stores; the probe opens the source DB `mode=ro` (verified) — nothing wrote to the clinical DB.
10. No resumption of engineering, benchmarks, or other threads until the user explicitly resumes.

This review is independent advice for the owner's synthesis; it is not professional or clinical signoff, and same-family independence limits apply as stated at the top.
